Cabaletta Bio
Cabaletta Bio is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Their proprietary CABA® platform aims to deliver deep, durable, and potentially curative responses with one-time administration, potentially eliminating the need for chronic immunosuppression. They are developing innovative therapies, including CABA-201, for diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, and myasthenia gravis, among others. The company emphasizes a mission to harness the immune system to deliver accessible cures and aims to develop the first targeted cellular therapies for autoimmune diseases.
Industries
Nr. of Employees
medium (51-250)
Cabaletta Bio
Products
Investigational CD19-targeting CAR T therapy (4-1BB co-stimulatory domain)
An investigational, fully human CD19-targeting CAR T cell therapy incorporating a 4-1BB co-stimulatory domain, developed as a one-time infusion to deplete B cells for potential immune reset in autoimmune diseases.
CAAR T candidate targeting DSG3 for pemphigus vulgaris
A chimeric autoantibody receptor T candidate designed to selectively eliminate autoreactive B cells recognizing DSG3, intended to treat mucosal pemphigus vulgaris by antigen-specific targeting.
CAAR T candidate targeting MuSK autoantibody-producing B cells
A chimeric autoantibody receptor T candidate developed to eliminate MuSK autoantibody-producing B cells for patients with MuSK myasthenia gravis.
Investigational CD19-targeting CAR T therapy (4-1BB co-stimulatory domain)
An investigational, fully human CD19-targeting CAR T cell therapy incorporating a 4-1BB co-stimulatory domain, developed as a one-time infusion to deplete B cells for potential immune reset in autoimmune diseases.
CAAR T candidate targeting DSG3 for pemphigus vulgaris
A chimeric autoantibody receptor T candidate designed to selectively eliminate autoreactive B cells recognizing DSG3, intended to treat mucosal pemphigus vulgaris by antigen-specific targeting.
CAAR T candidate targeting MuSK autoantibody-producing B cells
A chimeric autoantibody receptor T candidate developed to eliminate MuSK autoantibody-producing B cells for patients with MuSK myasthenia gravis.
Services
Early-phase clinical development for engineered T cell therapies
Design and execution of Phase 1/2 clinical trials for cell therapy candidates in autoimmune diseases, including site coordination, patient enrollment and trial operations.
CMC strategy, process development and manufacturing planning
Process development, analytical method development, manufacturing sciences and CMC planning to support clinical supply, regulatory filings and scale-up toward commercial manufacture.
Preclinical and translational research services
Discovery, target validation and translational studies to generate mechanism-of-action and biomarker data supporting IND-enabling packages for engineered T cell products.
Quality, compliance and regulatory support
Development and implementation of quality and compliance programs for clinical development, including auditing, regulatory monitoring and risk management to support submissions and inspections.
Scientific communications and congress presentation support
Preparation and dissemination of clinical and translational data for presentation at scientific conferences and in public press materials.
Investor reporting and SEC filing preparation
Preparation of periodic financial reports and regulatory filings for investors, including Form 10-Q filings and associated XBRL-tagged financial disclosures.
Early-phase clinical development for engineered T cell therapies
Design and execution of Phase 1/2 clinical trials for cell therapy candidates in autoimmune diseases, including site coordination, patient enrollment and trial operations.
CMC strategy, process development and manufacturing planning
Process development, analytical method development, manufacturing sciences and CMC planning to support clinical supply, regulatory filings and scale-up toward commercial manufacture.
Preclinical and translational research services
Discovery, target validation and translational studies to generate mechanism-of-action and biomarker data supporting IND-enabling packages for engineered T cell products.
Quality, compliance and regulatory support
Development and implementation of quality and compliance programs for clinical development, including auditing, regulatory monitoring and risk management to support submissions and inspections.
Scientific communications and congress presentation support
Preparation and dissemination of clinical and translational data for presentation at scientific conferences and in public press materials.
Investor reporting and SEC filing preparation
Preparation of periodic financial reports and regulatory filings for investors, including Form 10-Q filings and associated XBRL-tagged financial disclosures.
Expertise Areas
- Engineered T cell therapies for autoimmune diseases
- Antigen-specific B cell targeting strategies
- Early-phase (Phase 1/2) clinical development and multicenter operations
- CMC and clinical manufacturing scale-up for cell therapies
Key Technologies
- Chimeric antigen receptor T cell engineering
- Chimeric autoantibody receptor T engineering
- Targeted CD19 B-cell depletion strategies
- Co-stimulatory domain engineering